CanSino Biologics, Inc. Class H (HK:6185) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
CanSino Biologics Inc. has announced the initiation of Phase II/III clinical trials for its new Tdcp Adolescent and Adult booster vaccine, aimed at addressing the absence of an approved diphtheria, tetanus, and acellular pertussis booster for individuals aged six and above in China. This development promises to fill a crucial gap in the domestic market and enhance vaccine stability with improved manufacturing processes. Investors are advised to remain cautious while dealing in company shares.
For further insights into HK:6185 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue